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Abstract
Background: Oral squamous cell carcinoma is an aggressive neoplasm with serious morbidity and mortality, which
typically spreads through local invasive growth. Lysophosphatidic acid (LPA) is involved in a number of biological
processes, and may have a role in cancer cell migration and invasiveness. LPA is present in most tissues and can
activate cells through six different LPA receptors (LPAR1-6). Although LPA is predominantly promigratory, some of
the receptors may have antimigratory effects in certain cells. The signalling mechanisms of LPA are not fully
understood, and in oral carcinoma cells the specific receptors and pathways involved in LPA-stimulated migration
are unknown.
Methods: The oral carcinoma cell lines E10, SCC-9, and D2 were investigated. Cell migration was studied in a
scratch wound assay, and invasion was demonstrated in organotypic three dimensional co-cultures. Protein and
mRNA expression of LPA receptors was studied with Western blotting and qRT-PCR. Activation of signalling proteins
was examined with Western blotting and isoelectric focusing, and signalling mechanisms were further explored
using pharmacological agents and siRNA directed at specific receptors and pathways.
Results: LPA stimulated cell migration in the two oral carcinoma cell lines E10 and SCC-9, but was slightly inhibitory
in D2. The receptor expression profile and the effects of specific pharmacological antagonist and agonists indicated
that LPA-stimulated cell migration was mediated through LPAR3 in E10 and SCC-9. Furthermore, in both these cell
lines, the stimulation by LPA was dependent on PKC activity. However, while LPA induced transactivation of EGFR
and the stimulated migration was blocked by EGFR inhibitors in E10 cells, LPA did not induce EGFR transactivation
in SCC-9 cells. In D2 cells, LPA induced EGFR transactivation, but this was associated with slowing of a very high
inherent migration rate in these cells.
Conclusion: The results demonstrate LPA-stimulated migration in oral carcinoma cells through LPAR3, mediated
further by PKC, which acts either in concert with or independently of EGFR transactivation.
Keywords: Carcinoma, Epidermal growth factor receptor, Lysophosphatidic acid, LPA receptors, Cell migration,
Invasion, Coculture
Background
Oral cancers, the majority of which are squamous cell car-
cinomas, are aggressive neoplasms associated with serious
morbidity and considerable mortality [1,2]. A typical fea-
ture of these tumours is that they spread largely through
progressive local invasive growth [3]. Therefore, much
effort is currently directed at understanding the biological
mechanisms of the invasive behaviour of oral cancers [4].
Cell migration is controlled by several mechanisms, in-
cluding complex interactions between the tumour and its
stroma [5,6]. Many biologically active substances in the
microenvironment, including growth factors, chemokines
and various other locally active agents, can induce and
regulate cell migration and tumour invasiveness. These
substances may be produced by the carcinoma cells or the
stromal cells, or both, participating in autocrine or para-
crine mechanisms. It is important to understand in detail
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the role of factors that regulate cell migration and the sig-
nalling mechanisms by which they exert their effects in
oral cancer. Crucial steps in the invasive process have re-
cently received attention as potential treatment targets, ac-
knowledging the fact that without cell migration, no cell
invasion and tumour spread will occur [7].
Several receptors may participate in the control of cell
migration. Receptor tyrosine kinases (RTKs), which con-
vey signals from polypeptide growth factors, are of funda-
mental importance in cell regulation, and if deregulated
they may be involved in tumorigenesis [8]. Cellular effects
mediated by RTKs typically include stimulated prolifera-
tion, enhanced viability, and increased migration [8]. Not-
able examples of RTKs that can stimulate migration are
the epidermal growth factor (EGF) receptor (EGFR ),
which is the receptor for the EGF family of growth factors,
and Met, which is the receptor for hepatocyte growth fac-
tor (HGF, also termed scatter factor, SF) [9-11]. Several
signalling pathways may be involved in mediating the
stimulation of cell migration and invasion exerted through
these receptors. We have previously shown that both EGF
and HGF stimulate migration through the phosphoinosi-
tide 3-kinase (PI3K)/Akt, the MEK/ERK, and the p38
pathways in oral squamous carcinoma cell lines [12]. An-
other type of receptors that may play important roles in
regulation of cell migration is the large family of G-
protein-coupled receptors (GPCRs) [13-15]. Members of
this receptor family mediate the effects of numerous fac-
tors or other stimuli, including many classical hormones
and a variety of locally active substances, such as chemo-
kines, bioactive lipids, and other stromal components.
They act via selective interactions with specific heterotri-
meric G proteins which specifically couple the receptor
activation to one or several downstream pathways [16,17].
Through these mechanisms, the GPCRs transduce signals
regulating a variety of cellular processes, including prolif-
eration, viability and migratory activity. Some of these ef-
fects depend on interaction between the GPCRs and
receptor tyrosine kinases, particularly EGFR [16-21].
Lysophosphatidic acid (LPA) is a glycerophospholipid
which is present in all animal tissues and cells and is in-
volved in a large range of physiological functions and
pathological conditions and may have a role in cancer
[22-24]. LPA is produced mainly by the enzyme auto-
taxin (lysophospholipase D), and it exerts its functions
through the activation of one or more of at least six dif-
ferent receptors. The receptors, named LPAR1-6, all be-
long to the GPCR family, but are coupled to different
downstream signalling pathways and cellular responses
[24]. As LPA is abundantly present in saliva, it has a
large impact on oral epithelial cells and participates in
wound healing, at least in part by inducing epithelial cell
migration [25]. In oral squamous cell carcinoma (OSCC)
cell lines, LPA has been reported to induce migration
[26,27]. Due to its ability to induce cell migration and inva-
sion, LPA, its receptors, and autotaxin have been proposed
as novel targets for cancer treatment [22,28]. However, LPA
has also been found to inhibit migration in melanoma cells,
and thereby act as a tumour suppressor [29]. To date, very
little information exists about which LPA receptors are
present and active in oral carcinoma cell lines.
The aim of this study was to investigate to what extent
LPA affects migration in oral cancer cell lines and to
examine some of the underlying mechanisms. The work
focused particularly on two aspects. First, since little is
known about which mechanisms LPA acts through in
control of migration, we have begun studies to identify the
specific receptors involved. Second, since it has previously
been found that other GPCR activators may exert mito-
genic effects both by interacting with EGFR signalling and
by other mechanisms in various cancer cells [20,21,30], we
have investigated the relative roles of EGFR-dependent
and EGFR-independent signalling in the regulation of mi-
gration in the oral cancer cells.
Methods
Materials
LPA (L-α-Lysophosphatidic acid, oleoyl, sodium, cat. #
L7260), neurotensin (NT), 12-O tetradecanoylphorbol-
13-acetate (TPA), epidermal growth factor (EGF) and
GF109203X hydrochloride were obtained from Sigma-
Aldrich, (Saint Louis, MO, USA). CXCL12 (recombin-
ant human CXCL12/SDF-1γ) was from R&D Systems
(Minneapolis, MN, USA). Dodecylphosphate (LP-105)
was from Enzo Life Sciences (Farmingdale, NY, USA).
1-oleoyl-2-methyl-sn-glycero-3-phosphotionate ((2S)-
OMPT) and N-{(1R)-2-hydroxy-1-[(phosphonooxy)
methyl]ethyl}(9Z)octadec-9-enamide (VPC31143(R))
were from Avanti Polar Lipids (Alabaster, AL, USA).
GM6001 (CAS 142880-36-2) was from Calbiochem
(Merck KGaA, Darmstadt, Germany). Prostaglandin E2
(PGE2) was from Cayman (Ann Arbor, MI, USA). Gefi-
tinib and cetuximab were kind gifts from AstraZeneca
(Division Oslo, Norway) and Merck-Serono (Merck
KGaA, Darmstadt, Germany), respectively. Ki16425 was
from Santa Cruz Biotechnology (CA, USA). Anti-
phospho-EGFR (Tyr 1173) was from Invitrogen (Paisley,
UK), anti-ERK1/2 (cat. # 4695), anti-p-ERK1/2 (Thr202/
Tyr204, cat. # 9106), anti-p-p38 (Thr180/Tyr182), anti-
phospho-Akt (Ser 473) and anti-GAPDH was from Cell
Signaling (Danvers, MA, USA) and anti-LPAR1/2/3
were from LSBio (LifeSpan BioSciences Inc., WA, USA).
Secondary goat anti-mouse and goat anti-rabbit IgG HRP-
conjugated antibodies were purchased from Bio-Rad
Laboratories (Hercules, CA, USA). The inhibitors SB203580,
PD98059 and LY294002 were all purchased from Calbio-
chem (Merck KGaA, Darmstadt, Germany) and dissolved in
DMSO (Sigma-Aldrich). Smart pool human On-target plus
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LPAR3 siRNA and Non-targeting Control Pool were from
Thermoscientific (GE Healthcare, Dharmacon Inc.).
Cell culture
PE/CA-PJ-49 clone E10 (hereafter termed E10, ECACC,
Salisbury, UK, originally supplied by Drs Kosmehl and
Berndt, Friedrich-Schiller University, Jena, Germany) were
from a tongue squamous cell carcinoma in a 57-year old
male patient. PE/CA-PJ41 (clone D2) (hereafter termed D2,
ECACC, originally supplied by Drs Kosmehl and Berndt,
Friedrich-Schiller University, Jena, Germany ) were from
the oral squamous epithelium of a 67 year old female. SCC-
9 (ATCC, Manassas, VA, USA) were from a tongue squa-
mous cell carcinoma in a 25-year old male patient. The E10
and D2 cells were cultured in Iscove’s modified Dulbecco’s
medium (IMDM)(Sigma-Aldrich, St. Louis, MO,USA) sup-
plemented with 10% FBS (Lonza, Walkersville, MD, USA),
2 mM L-glutamine (Cambrex), 1% Pen/Strep (Gibco). The
SCC-9 cells were cultured in DMEM-Ham’s F12 medium
(cat. # 12-615 F, Lonza) supplied with 400 ng/ml hydrocor-
tisone, 1% Pen/Strep (Gibco) and 10% FBS. All cell lines
were subcultured by trypsination (Trypsin-EDTA, Lonza).
Normal human fibroblasts were obtained from healthy
adults with written consent, as described previously [31].
Genotyping by the Powerplex® 16 system (Promega)
was performed at the Norwegian Radium Hospital, De-
partment of Tumour Biology, Oslo, Norway.
Wound scratch assay
Cell migration was monitored in a wound scratch assay as
described previously [12]. Briefly, a scratch was made with
a sterile 100 μl pipette tip in a confluent cell layer, washed
twice in physiologic saline, and then various stimulatory
or blocking agents were added in serum-free medium.
Wells were photographed at the beginning of the experi-
ment and after 24 h (E10-cells), 17 h (D2-cells) or 24 and
48 h (SCC-9 cells). Pictures were obtained with an F-view
camera and AnalySIS Image processing software mounted
on an Olympus IX81 inverted microscope with a 4x ob-
jective (Olympus Norge AS, Oslo, Norway). AxioVision
Rel.4.8 software (Carl Zeiss, Oslo, Norway) was used for
analysis.
Organotypic 3D cocultures
Three-dimensional coculture models were prepared as de-
scribed previously [31]. Briefly, normal human fibroblasts
from oral mucosa were embedded in a collagen matrix. E10
cells were seeded on top of the matrix the next day. At day
5, the cultures were lifted to air-liquid interface, resting on
the membrane of a transwell insert with the medium below
the membrane. LPA was added to the medium at every
medium exchange from day 4 and throughout the protocol
until harvesting the tissue at day 11. The organotypic tissue
was fixed in 4% paraformaldehyde, embedded in paraffin
and cut into 4 μm sections, mounted on glass slides and
stained with hematoxylin and eosin.
Western blotting
50.000 cells were seeded in each well of 12-well plates.
The cells were grown for 24 hours in complete IMDM
(Sigma-Aldrich), then in serum-free medium for 24 hours
before stimulation with LPA with or without specific in-
hibitors as indicated in Results. After stimulation, cells
were washed once with PBS, and scraped directly in
Laemmli buffer (4% SDS, 20% Glycerol, 120 mM Tris–
HCl, pH6.8, 0.006% bromphenol blue and 10% mercap-
toethanol), and aliquots of 20 μg protein were separated
on 10% polyacrylamide gels by electrophoresis under de-
naturing conditions. The proteins were transferred to
nitrocellulose membranes using a semidry transfer system
(Bio-Rad). The membranes were incubated with primary
antibody in Tris-buffered saline containing 0.1% Tween 20
(TBST) with 5% non-fat dry milk or BSA overnight at 4°C.
The blots were then washed three times in TBST and in-
cubated with HRP-conjugated secondary antibodies at
room temperature for 1 h. The blots were visualized with
LumiGLO® (KPL, Gaithersburg, MD).
siRNA transfection
E10 cells seeded in 12-well plates were transfected with
siRNA smart pool targeting human LPAR3 mRNA 3 h
after plating by the use of Lipofectamine 2000. The
medium was replaced and 100 μl transfection mixture
containing 3 μl Lipofectamine 2000 (Invitrogen, Carlsbad,
Ca) and 3 μl 20 μM LPAR3 ON-TARGET plus siRNA
(Dharmacon, Lafayette, CO) in OptiMEM was added pr
well (1 ml medium), giving a final concentration of 60 nM
siRNA. Control cells were transfected with the same
amount of ON-TARGET plus Non-targeting siRNA
(Dharmacon). Transfected cells were then cultured for
72 h and harvested for qPCR. The same procedure was
applied to cells seeded for the wound scratch assay, where
the wound was made 72 h after transfection.
NanoPro isoelectric focusing
50.000 cells were seeded in each well of 12-well plates.
The cells were grown for 24 hours in complete IMDM
(Sigma-Aldrich), then in serum-free medium for 24 hours
before stimulation with LPA with or without specific in-
hibitors as indicated in Results. Cells were lysed with
Bicine/CHAPS buffer with aqueous and DMSO inhibitor
mixes (Protein Simple, Santa Clara, CA, USA) on ice.
Lysates (0.1 mg/ml) were mixed with fluorescent pI
Standard Ladder 3, Ampholyte premix G2, pH 5–8 sep-
aration gradient (Protein Simple) and loaded into capil-
laries in a Cell Biosensis Protein Simple NanoPro 1000
system according to the manufacturer’s instructions.
Proteins were separated by capillary isoelectric focusing
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separation performed at 21 mW for 40 minutes and then
immobilized with UV light exposure for 70 s. Anti-
ERK1/2 antibody or anti-phospho ERK1/2 was then
applied to the capillaries and probed with secondary
anti-mouse IgG. The NanoPro machine performed auto-
mated wash steps with Wash buffer (Protein Simple).
Primary antibody was incubated for 2 hours and second-
ary antibody for 1 hour. Signal was detected with Lumi-
nol and Peroxide (Protein Simple) and imaged with a
CCD camera. Quantitation was performed with Com-
pass software (Protein Simple). The method is described
and validated by O’Neill et al. [32].
RT-PCR
Isolation of mRNA: RNAwas isolated with QIAGEN
RNeasy kit (Cat.No. 74106) according to the manufac-
turer’s description. RNA was treated with DNAse
(RNase-Free DNase Set, QIAGEN).
cDNA synthesis: cDNA was synthesized from 2.5 or
5 μg RNA with Superscript® III reverse transcriptase (Invi-
trogen, CA, USA) with oligo(dT) as primer according to
the manufacturer’s recommendation. Primers: Primer se-
quences were designed by use of NCBI/Primer-BLAST
software [33]. Primers used in this study with NCBI refer-
ence sequences (Invitrogen, CA): LPAR1: Forward primer
AAGCTCCCCATCCACCTATCT, Reverse primer CATT-
CATGGCTGTGAACTGGG. LPAR2: Forward primer
CTTCTACGTGCGGCGGCGAG, Reverse primer ACCA
CGAACGCCCCCAGGA. LPAR3: Forward primer CGGG
TGAACGTGAGCGGATGT, Reverse primer TCACTGC
CGCGATGACCAGA. LPAR4: Forward primer GCGGTT
TGCAGTAAAAAGCTGCGG, Reverse primer TTTCCT
CCCCAAGAAAGAGTGTGCT. LPAR5: Forward primer
CCCTGAGGAGGTCTCTGCTGC, Reverse primer CAT
GGCATTCACCTCCGGGGC. LPAR6: Forward primer
TCCCTCTGCTATGGCTCTTCCTCA, Reverse primer
TGAGGCCTTTTCCTCAGTTGCCA.
Real-time quantitative PCR (qRT-PCR): PCR assays
were analysed with an Applied Biosystems 7900HT Fast
Real-Time PCR System using Platinum SYBR Green qPCR
Supermix-UDG with ROX (cat. # 11744, Invitrogen, CA).
Data were analysed with the SDS software (ver. 2.2, Ap-
plied Biosystems), cycle of threshold (Ct) and variation in
baseline were calculated from each amplification plot.
Based on the Ct value and standard curves the relative in-
put amount of mRNA was calculated. The data were nor-
malized using GADPH as internal control.
Statistical analysis
Statistical analysis for the migration studies was per-
formed using Sigmaplot 11.2 (Systat software, Inc., San
Jose, CA, USA). Mean percent wound closure of groups
was compared using t-test for normally distributed data
and Mann–Whitney rank-sum test when data were not
normally distributed. A difference was considered to be
statistically significant where the corresponding p-value
was ≤0.05. Exact p-values are given in figure legends.
Densitrometic analyses of immunoblots were obtained
with ImageJ (National Institutes of Health, Bethesda,
Maryland, USA). Data were expressed as mean ± SEM
from independent experiments and visualized with
GraphPad Software. The statistical significance of dif-
ferences was analysed by unpaired t-test using Graph-
Pad Software.
Results
Effect of LPA on migration and invasive activities in OSCC
cell lines
We first tested the effects of several GPCR agonists on
migration, using scratch wound healing in the E10 cell
line as an experimental model. In previous work on
these cells we determined optimal conditions for such
studies, demonstrated strong effects of both EGF and
HGF on the migration, and could investigate underlying
signalling mechanisms [12]. While neither CXCL12,
PGE2 nor NT were found to be powerful activators of
migration in E10 cells, LPA induced a strong dose-
dependent migratory response, which at 24 h was max-
imal at 10 μM, with ED50 at about 2 μM (Figure 1A,B).
Furthermore, we examined the effect of LPA on two add-
itional oral carcinoma cell lines. We found that LPA also
stimulated cell migration in the SCC-9 cells (Figure 1A,B).
On the other hand, LPA had a slightly inhibitory effect on
migration in the D2 cells, a cell line that is highly migra-
tory without stimulation. We observed full wound
closure in the D2 cells by approximately 17 h in
serum-free medium without LPA, while the migration
was slower and wound closure occurred several hours
later in the presence of 10 μM LPA. In further experi-
ments, 10 μM LPA was chosen as the preferred dose
for all the cells, and readout for cell migration was set
at 24 h for the E10 cells, 48 h for the SCC-9 cells, and
17 h for the D2 cells.
To examine if stimulation of migration by LPA was
reflected in enhanced invasiveness, we tested the cap-
acity of LPA to induce cellular invasion in three-
dimensional (3D) culture. For this purpose we used an
organotypic 3D model consisting of human oral fibro-
blasts embedded in a collagen I matrix with E10 carcin-
oma cells seeded on top [31]. After 11 days of co-culture,
a multilayer squamous carcinoma epithelium had formed
on top of the matrix (Figure 1C). The 3D cultures were
kept with or without LPA in the medium. We consistently
found that LPA increased the tendency of the carcinoma
cells to invade the fibroblast/collagen layer, with more
tumour cell islands in the connective tissue compartment
than in untreated controls (Figure 1C).
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Expression of LPA receptors in OSCC cell lines
We next started studies aiming at understanding which
receptors are mediating the effects of LPA on migration
in the oral carcinoma cells. Present evidence indicates
that there are at least six different LPA receptors [34].
Studies in other cells have shown varying expression of
LPA receptors. Qualitative RT-PCR revealed that both
the E10 and the SCC-9 cells expressed LPAR1, 2, 3, 4, 5,
and 6 mRNA at different levels (Figure 2A). For protein
expression, we focused on the EDG-family members of
LPA receptors, i.e. LPAR1-3. Antibodies against LPAR4-
6 did not show adequate specificity in our cells and were
not used. The LPAR1 protein was not expressed on
Western blots in the E10 and the SCC-9 cells, but was
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Figure 1 Effect of LPA on migration and invasiveness in oral carcinoma cells. A: The effect of various GPCR ligands on cell migration. Cell
migration was observed after scratch wounding in a confluent cell layer. Various GPCR ligands were added to the wells with serum-free medium
as indicated. Digital images were obtained immediately after stimulation and after 17 h (D2), 24 h (E10) or 48 h (SCC-9) and wound closure was
measured. The dark marks on the images were made to orient the picture and ensure that they were from the same location. B: Dose-dependent
wound closure with LPA stimulation in the E10, SCC-9 and D2 cells. Cell migration was measured after scratch wounding in a confluent cell layer as
in A. LPA was added to the wells with serum-free medium as indicated. Digital images were obtained immediately after stimulation and after
17 h (D2), 24 h (E10) or 48 h (SCC-9) and per cent wound closure was measured. Bars represent mean ± SEM (Standard error of the mean), n = 5.
Left: Dose/response curve for one experiment in E10 cells is shown with doses from 0 to 100 μM, indicating a near maximal effect at 24 h using
10 μM LPA. 10 μM of LPA was chosen for use in further experiments. C: Organotypic coculture model without (left) and with (right) 10 μM LPA
added during day 4 to 11 of culture.
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present in the D2 cells. Another oral carcinoma cell line,
C12, which was employed for comparison, also strongly
expressed LPAR1. All the cells studied expressed LPAR2
and LPAR3 proteins (Figure 2B).
Effects of pharmacological agents acting on specific LPA
receptors
To further study the role of the different LPA receptors,
we examined functional response in cells treated with
different receptor-specific agonists, focusing on LPAR1-
3 (Figure 3). First, we used the agonist VPC31143(R),
originally thought to be specific for LPAR1 [35]. This
agonist stimulated phosphorylation of ERK in E10 and
SCC-9 cells (Figure 3A). However, more recently it has
been shown that VPC31143(R), a NAEPA (N-acyl etha-
nolamide phosphate)-derived LPA agonist, activates all
the LPARs [34], which is more compatible with the ex-
pression data since LPAR1 protein was not detected in
E10 or SCC-9 cells (Figure 2). To our knowledge, other
more specific LPAR1 agonists are not available at the mo-
ment. The LPAR2-specific agonist LP-105 (also named
FAP12) gave only a weak phosphorylation of EGFR, Akt,
and ERK as compared to LPA in the E10 cells, and no de-
tectable phosphorylation of EGFR, Akt, or ERK in the
SCC-9 cells (Figure 3A). However, the LPAR3-specific
agonist (2S)-OMPT readily induced phosphorylation of
EGFR, Akt, and ERK in the E10 cells and, more weakly, in
SCC-9 (Figure 3A). Using E10 cells as a model, we also
found that (2S)-OMPT induced cell migration of about
the same magnitude and slightly higher potency than
LPA, with a maximal effect at ≥2.5 μM and ED50 at about
0.5 μM (Figure 3B, right). VPC31143(R) also stimulated,
while LP-105 had no effect on migration in the E10 cells
(Figure 3B).
Very few commercially available LPAR inhibitors exist,
and they mainly target LPAR1 and/or LPAR3. The LPA in-
hibitor Ki16425 is known to inhibit both LPAR1 and
LPAR3. We found that Ki16425 inhibited the ability of
LPA to induce migration in both the E10 and SCC-9 cells,
which, in view of our failure to demonstrate expression of
LPAR1 protein, is additional support for LPAR3 being in-
volved (Figure 4A). However, in the E10 cells, the inhib-
ition was not complete, suggesting that these cells might
have other active LPA receptors. Ki16425 also inhibited
the migration induced by the LPAR3-specific agonist (2S)-
OMPT in E10 cells, providing further support for
LPAR3 as a mediator of the LPA effect (Figure 4B). In
the SCC-9 cells, the Ki16425 completely inhibited the
LPA-induced migration, decreasing it to a level below
the controls, suggesting a basal activity of LPAR3 in the
SCC-9 cells (Figure 4A). In the D2 cells, no significant ef-
fect of Ki16425 on migration was observed (Figure 4A).
Ki16425 also had a partial inhibitory, statistically signifi-
cant effect on EGF-induced cell migration in E10 cells
(p = 0.03), while the effect in SCC-9 cells was not sig-
nificant (Figure 4C). We then investigated the effect of
the LPAR blocker Ki16425 on LPA-induced phosphor-
ylation of signalling molecules. In the E10 cells, Ki16425
inhibited, although not completely, the phosphorylation of
EGFR, Akt, ERK and p38 (Figure 4D). Although LPA-
induced migration was inhibited with Ki16425 in the
SCC-9 cells, this inhibitor had no effect on the immediate
phosphorylation of ERK, but slightly reduced Akt and p38
phosphorylation (Figure 4D).
To further validate the results obtained with LPA and
inhibitors, we assessed some of the responses with isoelec-
tric focusing as a supplement to Western blots. ERK1/2
phosphorylation in E10 cells was used as a model, and iso-
electric focusing combined with immunodetection was
performed with the NanoPro system [32]. Figure 5A
shows a typical pI spectrum for ERK1/2 probed with anti-
body against total ERK1/2 in unstimulated (upper left)
and LPA-stimulated (upper right) cells. The profile shows
that upon LPA treatment, there was a shift from unpho-
sphorylated to phosphorylated ERK1/2 signals. The peaks
corresponding to phosphorylated ERK were verified with a
phosphospecific ERK antibody (lower panels). The low
level of phosphorylated ERK seen in the unstimulated
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Figure 2 LPA receptors present in oral carcinoma cell lines. mRNA and protein levels were detected in lysates from subconfluent,
unstimulated cells. A: qRT-PCR shows that mRNA encoding LPAR1-6 was present in unstimulated E10 and SCC-9 cells. n = 4. Bars represent mean
± SEM. B: Western blots show LPAR1 (at 41 kDa), LPAR2 (at 39 kDa) and LPAR3 (at 40 kDa) protein in unstimulated E10 and SCC-9 cells. n = 3. Due
to a very weak LPAR2 band in the SCC-9 cells, the same blot is shown twice with normal and increased exposure for visualisation.
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samples with the pan-ERK antibody, as also seen in the
Western blots, was not detected in the NanoPro system
with the phosphospecific antibody, for reasons that we
at present cannot fully explain. Figure 5B shows quanti-
fication of data, based on the use of the pan-ERK anti-
body, from 3 experiments generated in principle as in
Figure 5A. The results demonstrate that the stimula-
tion of ERK phosphorylation after addition of LPA was
significantly inhibited by Ki16452 (p = 0.018). These data
are well in accordance with the findings with immunoblot-
ting (Figure 4D). Using the NanoPro technique, we have
also performed similar analyses of the effects of other
blockers of specific pathways (see below).
To further examine the effect of LPAR3 on LPA-
stimulated cell migration, we pretreated the cells with
siRNA against LPAR3 (Figure 6). The LPAR3 siRNA did
not block LPA-induced cell migration, but the migration
was still inhibited by the use of LRAR1/3-inhibitor
Ki16425 (Figure 6B). We then examined the expression of
LPAR1 and LPAR2 upon the use of LPAR3 siRNA, and
found that LPAR1 and 2 mRNA were upregulated while
LPAR3 mRNA was (partly) downregulated (Figure 6A).
This suggests that LPAR3 was not sufficiently suppressed
and/or that LPAR1 may take over as an inducer of cell mi-
gration when LPAR3 has been downregulated. The effect
of LPAR2 was examined using the specific agonist LP-105.
Although we saw an upregulation of LPAR2 mRNA after
LPAR3 silencing, this agonist did not induce migration,
neither in the absence nor the presence of the concomi-
tant use of LPAR1/3 inhibitor.
Role of protein kinase C (PKC), downstream pathways and
EGFR in LPA-induced migration
We studied the possible role of protein kinase C (PKC)
in regulation of LPA-induced migration. PKC has been
found to play a role in many cancer cells [36]. We exam-
ined whether the LPA-stimulated migration was affected by
inhibition of PKC. In both the E10 and the SCC-9 cells,
treatment with the PKC inhibitor GF109203X almost com-
pletely inhibited LPA-induced cell migration (Figure 7A).
Further evidence of a role for PKC was obtained with the
use of tetradecanoyl phorbol acetate (TPA), a direct ac-
tivator of PKC. TPA induced cell migration in both E10
and SCC-9 and this effect was inhibited by GF109203X
(Figure 7A). Addition of the PKC inhibitor before the
stimulation with EGF resulted in a considerable
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inhibition of the migration in the E10 cells, but only had
a minor, however significant inhibitory effect in the
SCC-9 cells (Figure 7A).
The importance of downstream kinase pathways in
cell migration was studied. Blocking of the MEK/ERK
kinase, the p38 kinase and the PI3 kinase with PD98059,
SB203580, and LY294002 respectively, all inhibited the
LPA-induced cell migration in the E10 cells (Figure 7B).
EGF was previously found to strongly stimulate migra-
tion in several oral cancer cells, including E10 [12], and
transactivation of EGFR has been found to be part of the
mechanism of mitogenic effects of GPCRs in several
cancer cells [20,21,30,37]. We now investigated the role
of EGFR signalling in the stimulation of migration by
LPA. Blocking of the EGFR with the EGFR tyrosine kin-
ase inhibitor gefitinib or the EGFR antibody cetuximab
inhibited LPA-stimulated cell migration down to control
level or below in E10 and SCC-9 cells (Figure 7C, top
and middle panel). This suggests a role for EGFR in the
cellular response to LPA, in terms of either a necessary
synergism between downstream signalling pathways or an
LPA-induced transactivation of EGFR. In the D2 cells gefi-
tinib, but not cetuximab, reduced the inherent cell migra-
tion, conceivably reflecting differences related to inhibition
of the extracellular ligand binding site versus the intracellu-
lar kinase site. The effect of gefitinib in D2 cells was more
pronounced in the presence of LPA (Figure 7C, bottom
panel).
EGFR and downstream pathways in LPA signal
transduction
Figure 8A shows that in E10 cells stimulated with LPA,
there was a marked and rapid phosphorylation of EGFR
(at Tyr 1173) as well as the downstream signalling mole-
cules ERK, Akt, and p38. When E10 cells were treated
with gefitinib, the LPA-induced phosphorylation of
EGFR was blocked, the effects on Akt and p38 were
strongly inhibited, and the effect on ERK was completely
abolished. The effect of gefitinib and cetuximab on ERK
phosphorylation in LPA-stimulated E10 cells was studied
further by use of isoelectric focusing in the NanoPro de-
tection system. Here, we could demonstrate that LPA
induced phosphorylation of ERK1/2, and that the phos-
phorylation was inhibited when the cells were pre-treated
with cetuximab or gefitinib, confirming the Western blot
results (Figure 8B). In contrast to the E10 cells, SCC-9
cells treated with LPA did not exhibit any phosphorylation
of EGFR or any other tyrosine phosphorylation corre-
sponding to the size of the ErbB family protein detected
with a phosphotyrosine antibody (Figure 8A, middle and
8C). For comparison, EGF induced strong tyrosine phos-
phorylation in these cells (Figure 8C). In these cells LPA
induced strong phosphorylation of ERK, Akt, and p38, but
these effects were not sensitive to gefitinib. The D2 cells
responded to LPA in a manner very similar to the E10
cells, as EGFR, ERK, and Akt were phosphorylated, and
these effects were inhibited by gefitinib (Figure 8A, right).
Interestingly, cetuximab did not inhibit Akt in the D2
cells, which may reflect properties of the EGFR system in
these cells and corresponds to the failure of cetuximab to
inhibit migration in D2 cells.
Endogenously produced EGFR ligands can participate in
autocrine mechanisms and mediate EGFR transactivation,
thus enhancing EGFR-driven tumorigenesis. LPA has been
shown to activate MMP-2 in ovarian cancer [38]. To test
if LPA induced release of EGFR ligands in the oral carcin-
oma cells, we treated them with the matrix metallopro-
tease (MMP) inhibitor GM6001 prior to stimulation with
LPA (Figure 9). In the E10 cells, GM6001 strongly reduced
the phosphorylation of EGFR, Akt and ERK, suggesting
that LPA transactivated EGFR via the release of endogen-
ously produced EGFR ligands (Figure 9A). The p38 phos-
phorylation was unaffected. Isoelectric focusing using the
NanoPro detection system also showed that GM6001
inhibited the LPA-induced phosphorylation of ERK1/2 in
the E10 cells as shown in Figure 8B. In the SCC-9 cells,
the MMP inhibitor did not affect phosphorylation of Akt,
ERK or p38 (Figure 9A, middle), which is consistent with
the lack of sensitivity to gefitinib in these cells (Figure 8A).
In the D2 cells, like E10, GM6001 reduced LPA-induced
phosphorylation of EGFR and Akt and completely blocked
ERK phosphorylation (Figure 9A, right). We also exam-
ined the effect of the MMP inhibitor on migration. Treat-
ment of the E10 cells with GM6001 strongly reduced
(See figure on previous page.)
Figure 4 Inhibition of LPAR1 and 3 with Ki16425. A-C: Effect on cell migration. Cell migration was measured after scratch wounding in a
confluent cell layer. A: Inhibitor, solvent (DMSO) and/or LPA were added to the wells with serum-free medium as indicated. Digital images were
obtained immediately after stimulation and after 24 h (E10), 48 h (SCC-9) and 17 h (D2) and wound closure was measured. B: Inhibitor, solvent (DMSO)
and/or LPAR3 agonist OMPT at 48 h gave similar results as LPA at 24 h in E10 cells. C: Inhibitor, solvent and/or EGF were added as indicated in E10 and
SCC-9 cells. Digital images were obtained immediately after stimulation and after 24 h (E10), 48 h (SCC-9). Bars represent mean ± SEM, n = 3 or 4. The
following concentrations were used: LPA 10 μM, OMPT 2.5 μM, EGF 5 nM, Ki16425 1 or 10 μM as indicated. * indicates p < 0.001, **indicates p = 0.03,
NS = Not significant. D: Effects on EGFR, Akt, ERK and p38 phosphorylation. Subconfluent cell cultures were pre-treated with Ki16425 for 30 min, and then
stimulated with 10 μM LPA for 3, 5, 10 min (E10 cells) or 1, 3, 5 min (SCC-9 cells) as indicated. Cells were lysed for Western blotting. Western blots show
partial inhibition of Akt, ERK, p38 and EGFR phosphorylation in E10 cells (D left), while in SCC-9 cells (D right) very little inhibition was detected. No EGFR
phosphorylation with LPA was observed in SCC-9 cells. As a positive control, EGFR phosphorylation with EGF stimulation (abbreviated E) is shown.
Densitometric analyses of E10 cell at 5 min stimulation are shown below the E10 blots. *indicates p≤ 0.01.
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LPA-induced cell migration (Figure 9C). In the SCC-9 cells,
the pre-treatment gave only a partial and not significant re-
duction of the LPA-induced migration, corresponding to
the lack of effect on Akt, ERK, and p38 phosphorylation. In
D2 cells, GM6001 caused a small reduction of the basal,
non-stimulated, cell migration (Figure 9C).
Discussion
LPA can stimulate cell migration and invasion in several
cancers, including ovarian, pancreatic, various gastro-
intestinal, and oral carcinomas [22,39]. Clarification of
the mechanisms underlying LPA-induced cell migration
in oral carcinomas is of considerable interest due to the
fact that this cancer has a great tendency to spread by
local invasion. In this study, we first sought to determine
which receptors are involved in mediating the regulation
of migration by LPA in two oral carcinoma cell lines.
This is a complex issue, as six different LPARs have been
identified [24] and relatively few selective tools for inves-
tigating the roles of the individual receptors in specific
physiological and pathobiological processes are presently
available. Furthermore, since we have found that in sev-
eral cancer cells GPCR-conveyed mitogenic signals may
be mediated by pathways involving PKC or EGFR, or
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both in interaction [20], we also investigated the roles of
these mechanisms.
The present results suggested that, in the cell lines in
which LPA stimulated migration, LPAR3 was involved in
the effect. The E10 and the SCC-9 cells both expressed
LPAR2 and 3, but no LPAR1 protein. The D2 cell line,
which showed a slightly reduced migration upon LPA-
stimulation, expressed both LPAR 1, 2 and 3 proteins. The
LPAR1/3 inhibitor Ki16425 abolished the LPA-induced
migration in both E10 and SCC-9 cells, suggesting that
the LPAR3 receptor mediated the effect, given that no
LPAR1 was detected. These results correlated well with
inhibition of downstream signalling in these cells. When
Ki16425 was developed and shown to have preference for
LPAR1 and LPAR3, the only established LPA receptors
were LPAR1-3, and therefore the effect of this inhibitor on
other LPA receptors was not tested [40]. However, we are
not aware of any later reports suggesting that Ki16425 acts
on other receptors than LPAR1 or LPAR3. Ki16425 was
also found to inhibit EGF-induced migration in the E10
and SCC-9 cells. This could indicate that the inhibitor was
partially unspecific. However, in human ovarian carcinoma
cells, Snider et al. showed that EGF induced LPA produc-
tion, and the effect of EGF on migration was inhibited by
Ki16425 [41]. Thus, if part of the EGF-induced migration
is dependent on the secondary LPA production in our ex-
periments as well, this would explain why inhibition of
LPA receptors might reduce some of the EGF-mediated
cell migration. The LPA agonist VPC31143(R) stimulated
ERK phosphorylation and migration to about the same ex-
tent as LPA (Figure 3). This agonist was originally thought
to be specific towards LPAR1 [35], but has more recently
been shown to act via all the LPA receptors (LPAR1-6) like
LPA itself [34]. Most important, however, we could also
show that (2S)-OMPT, which has specificity for LPAR3
[42,43], stimulated ERK and Akt phosphorylation as well as
migration in a manner similar to LPA (Figure 3). In contrast,
the LPAR2-specific agonist LP-105 [44], did not mimic the
effects of LPA (Figure 3). Taken together, these results sug-
gest an involvement of LPAR3 in LPA-stimulated migration
in E10 and SCC-9 oral carcinoma cells. However, the results
could suggest that upon downregulation of LPAR3 with
siRNA in the E10 cells, LPAR1 may substitute for LPAR3,
but we have insufficient evidence for this.
We are not aware of other studies of receptors in-
volved in LPA-induced migration in oral carcinoma cells.
Studies in other cells have yielded varying results. LPAR3
has been implicated in ovarian cancer progression and cell
migration [45,46], but was also reported to inhibit cell mi-
gration and invasion in colon cancer cells [47]. LPAR1 has
been found to induce migration in cells from breast cancer
[48], pancreatic cancer [49], and hepatocellular carcinoma
[50] while it inhibited metastasis and invasion in prostate
organotypic models [51]. LPAR2 was found to mediate
LPA-induced invasion in endometrial cancer [52], but
seemed to have an inhibitory role in pancreatic cancer
[49]. In breast carcinoma cells both LPAR1 and 2 medi-
ated LPA-induced migration, where LPAR1 worked at
lower LPA-concentrations than LPAR2 and thus contrib-
uted to an effect over wider concentration ranges [53]. For
the non-EDG LPA-receptors, LPAR4-6, information on
their role in cancer is very limited and few studies exist.
LPAR4 has shown both antimigratory [54,55] and proinva-
sive effects [56]. LPAR5 inhibited migration [29], and
LPAR6 (synonymous to P2Y5) was thought to be pro-
cancerous [57].
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Brusevold et al. BMC Cancer 2014, 14:432 Page 12 of 16
http://www.biomedcentral.com/1471-2407/14/432
PKC may be involved in cancer progression [36].
LPAR3, which was found to be the most likely mediator
of the migratory effect of LPA in the oral cancer cells
studied here, is known to couple to Gq and phospholip-
ase C β (PLC-β) and can thus convey activation of PKC.
The LPA activity mediated by PKC was assessed in our
study by use of an inhibitor of PKC, GF109203X. The
inhibitor totally abolished the LPA-induced cell migra-
tion in SCC-9 cells. Furthermore TPA, a direct activator
of PKC, mimicked the effect of LPA in these cells, pro-
viding further support for a role of PKC. A different
mechanism was seen in the E10 cells, where both PKC
activation and EGFR transactivation were necessary for a
full migratory response to LPA. In these cells, TPA in-
duced a partial migratory response, while both the EGF-
and LPA-induced migration was inhibited by the PKC
inhibitor.
In both E10 and D2 cells, which have very different mi-
gratory responses to LPA, EGFR was rapidly transactivated
in response to LPA. This was associated with phosphoryl-
ation of Akt and ERK. In contrast, the SCC-9 cells, sharing
the pro-migratory outcome of LPA stimulation with the
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Figure 8 Role of EGFR in LPA signal transduction. Subconfluent cell cultures were pre-treated with 1 μM gefitinib for 30 min before stimula-
tion with 10 μM LPA for 1, 3 or 5 min as indicated. Cells were lysed for Western blotting or isoelectric focusing with NanoPro detection system as
described in Methods. A: Western blots show phosphorylation of EGFR, Akt, ERK and p38 after LPA stimulation. The phosphorylation was inhibited
by gefitinib pre-treatment in E10 and D2 cells. Cetuximab, in contrast to gefitinib did not inhibit Akt phosphorylation in D2 cells. In SCC-9 cells,
Akt, p38, and ERK were phosphorylated by LPA, but not inhibited by gefitinib. No phosphorylation of EGFR was detected after LPA stimulation in
the SCC-9 cells. As a positive control, EGFR phosphorylation after EGF stimulation was shown. n = 3. Graphs showing blot quantifications for E10
and D2 at 5 min are shown below the blots. B: NanoPro detection confirmed inhibition of LPA-induced ERK phosphorylation with gefitinib
(1 μM) in E10 cells. Similar results were seen with cetuximab (0.16 μM). C: Western blots show tyrosine phosphorylation of EGFR and total tyrosine
phosphorylation in SCC-9 cells after stimulation with EGF. No tyrosine phosphorylation is detected after LPA stimulation. n = 3 *indicates p≤ 0.01.
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E10 cells, showed no evidence of LPA-induced EGFR trans-
activation, but LPA induced EGFR-independent phosphor-
ylation of ERK and Akt. These results were strengthened by
the finding that inhibition of MMP by GM6001 closely
mimicked the effects of gefitinib and cetuximab in E10, but
did not affect SCC-9. Taken together, these results strongly
suggest that LPA elicits rapid EGFR transactivation in E10
and D2, but not in SCC-9 cells. The lack of EGFR transacti-
vation in SCC-9 cells is in conflict with findings in another
study where transactivation in these cells was reported [27].
Because of these discrepant results, we tested our SCC-9
cells for authenticity. According to the genotyping, our cells
were not altered after leaving the ATCC. However, the ab-
sence of any evidence of transactivation of EGFR by LPA in
SCC-9 within the first few minutes does not rule out the
possibility that transactivation might occur after longer ex-
posure to LPA. EGFR activity via GPCR with a longer lag
time has been described. This might have relevance to our
results, since the LPA-induced migration in the SCC-9 cells
was inhibited by gefitinib and cetuximab (Figure 7C) and to
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transduction was examined by use of MMP-inhibitor GM6001. Subconfluent cell cultures were pre-treated with 10 μM GM6001 for 30 min, then
stimulated with 10 μM LPA for 1, 3 or 5 min as indicated. Cells were lysed for Western blotting or isoelectric focusing with NanoPro detection
system as described in Methods. A: Western blots show the inhibition of LPA-induced EGFR, Akt and ERK phosphorylation in E10 and D2 cells,
but no inhibition in SCC-9 cells. Graphs showing blot quantifications for E10 and D2 at 5 min are shown below the blots. B: NanoPro detection
confirmed the partial ERK inhibition in E10 cells, however not statistically signinficant. C: Role of membrane-bound ligand in cell migration. Cell
migration was detected after scratch wounding in a confluent cell layer. Inhibitor, solvent (DMSO) and/or LPA was added to the wells with
serum-free medium as indicated. Digital images were obtained immediately after stimulation and after 17 h (D2), 24 h (E10) and 48 h (SCC-9)
and wound closure was measured. Bars represent mean ± SEM, n = 3 or 4. LPA 10 μM, GM6001 10 μM. *indicates p ≤ 0.05, NS = Not significant.
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some extent also by GM6001 (Figure 8C). It is conceivable
that a time-dependent EGFR ligand production in these
cells could occur during the 48 h observation, thus explai-
ning the sensitivity to inhibition by gefitinib and cetuximab
despite no evidence of transactivation in the short-term
experiments.
Conclusion
While studies in various cancers indicate that different
receptors may be involved in LPA-regulated cell migra-
tion, our present results strongly suggest that in the two
oral cancer cell lines where LPA stimulated the migra-
tion, E10 and SCC-9, the effect was mediated by LPAR3.
However, the cells differed with respect to downstream
pathways. In the E10 cells, the stimulation via LPAR3
led to a concerted activation of PKC and transactivation
of EGFR, both of which being required for full migratory
response. In the SCC-9 cells, activation of PKC was cru-
cial for LPA-induced migration, while there was no evi-
dence of EGFR transactivation, although activation of
EGFR upon longer culturing was not excluded. In a third
oral carcinoma cell line, D2, LPA caused rapid EGFR
transactivation, like in E10 cells, but D2 cells have a very
high migratory activity in the absence of any stimulation,
and LPA is rather slightly inhibitory. Thus, although the
data show some common features in the mechanisms in-
volved in the response to LPA in these oral carcinoma cell
lines, they clearly demonstrate that there are important
differences. Further studies are required both to get a
better understanding of the degree of heterogeneity in oral
carcinomas in terms of LPA signalling and to explore
mechanisms that might provide therapeutic targets.
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